UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO

RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of November 2021

 

Commission File Number: 001-38396

 

BIOFRONTERA AG

(Registrant’s name / Translation of registrant’s name into English)

 

Hemmelrather Weg 201, D-51377 Leverkusen Germany

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form:40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): N/A

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): N/A

 

 

 

 

 

 

EXHIBITS

 

Exhibit Number   Description
99.1   Biofrontera reaches out-of-court settlement with DUSA Pharmaceuticals, Inc.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  BIOFRONTERA AG
     
  By: /s/ Hermann Lübbert
  Name: Hermann Lübbert
  Title: Chief Executive Officer

 

Date: November 29, 2021

 

 
Biofrontera (NASDAQ:BFRA)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Biofrontera Charts.
Biofrontera (NASDAQ:BFRA)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Biofrontera Charts.